key: cord-0938380-le7c2zsz authors: Fallerini, C.; Daga, S.; Mantovani, S.; Benetti, E.; Pujol, A.; Picchiotti, N.; Schluter, A.; Planas-Serra, L.; Troya, J.; Baldassarri, M.; Fava, F.; Ludovisi, S.; Castelli, F.; Quiros-Roldan, M. E.; Vaghi, M.; Rusconi, S.; Siano, M.; Bandini, M.; Furini, S.; Mari, F.; GEN-COVID Multicenter Study,; Renieri, A.; Mondelli, M. U.; Frullanti, E. title: Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males date: 2020-11-27 journal: nan DOI: 10.1101/2020.11.19.20234237 sha: 7cade898f31cfdb6ab7011d5d7a6176ce3136460 doc_id: 938380 cord_uid: le7c2zsz Background: COVID-19 clinical presentation ranges from asymptomatic to fatal outcome. This variability is due in part to host genome specific mutations. Recently, two families in which COVID-19 segregates like an X-linked recessive monogenic disorder environmentally conditioned by SARS-CoV-2 have been reported leading to identification of loss-of-function variants in TLR7. Objective: We sought to determine whether the two families represent the tip of the iceberg of a subset of COVID-19 male patients. Methods: We compared male subjects with extreme phenotype selected from the Italian GEN-COVID cohort of 1178 SARS-CoV-2-infected subjects (<60y, 79 severe cases versus 77 control cases). We applied the LASSO Logistic Regression analysis, considering only rare variants on the young male subset, picking up TLR7 as the most important susceptibility gene. Results: Rare TLR7 missense variants were predicted to impact on protein function in severely affected males and in none of the asymptomatic subjects. We then investigated a similar white European cohort in Spain, confirming the impact of TRL7 variants. A gene expression profile analysis in peripheral blood mononuclear cells after stimulation with TLR7 agonist demonstrated a reduction of mRNA level of TLR7, IRF7, ISG15, IFN-[a] and IFN-{gamma} in COVID-19 patients compared with unaffected controls demonstrating an impairment in type I and II INF responses. Conclusion: Young males with TLR7 loss-of-function mutations and severe COVID-19 in the two reported families represent only a fraction of a broader and complex host genome situation. Specifically, missense mutations in the X-linked recessive TLR7 disorder may significantly contribute to disease susceptibility in up to 4% of severe COVID-19. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; Coronavirus disease 2019 (COVID-19), a potentially severe systemic disease caused by coronavirus SARS-CoV-2, is characterized by a highly heterogeneous phenotypic variability, with the large majority of infected individuals experiencing only mild or even no symptoms. However, severe cases can rapidly evolve towards a critical respiratory distress syndrome and multiple organ failure 1 . COVID-19 still represents an enormous challenge for the world's healthcare systems ten months after the first appearance in December 2019 in Wuhan, Huanan, Hubei Province of China. Symptoms of COVID-19 range from fever, cough, sore throat, congestion, anosmia and fatigue to shortness of breath, interstitial pneumonia followed by respiratory distress and septic shock 1 . Although older age and the presence of cardiovascular or metabolic comorbidities have been identified as risk factors predisposing to severe disease 2 , these factors alone do not fully explain the differences in the severity. Male patients show more severe clinical manifestations than females with higher prevalence of hospitalizations (16% versus 12%), ICU admissions (3% versus 2%), and deaths (6% versus 5%), indicating that gender may influence the outcome of the disease 3 . These findings suggest a role of host predisposing genetic factors in the pathogenesis of the disease which may be responsible for different clinical outcomes as a result of different antiviral defence mechanisms as well as specific receptor permissiveness to virus and immunogenicity. More than that, recent evidences suggest also a fundamental role of IFN genes in genetic bases of COVID-19; in particular, recently rare variants have been identified in the interferon type I pathway that are responsible for inborn errors of immunity in a small percentage of patients and auto-antibodies against type I interferon genes in up to 10% of severe COVID-19 cases 4,5 . Toll-like receptors (TLRs) are crucial components in the initiation of innate immune response -the non specific-immune response-to a variety of pathogens, causing the production of pro-inflammatory cytokines (TNF-α, IL-1, and IL-6) and type I and II IFNs, that are responsible for innate antiviral responses. In particular the innate immune response is very sensitive in detecting potentially pathogenic antigens, activating downstream signaling to induce transcription factors in the nucleus, promoting synthesis and release of types I and type III interferons (IFNs) in addition to a number of other important proinflammatory cytokines. However, when the immune response is dysregulated, it can result in excessive inflammation, or in extreme cases, death. Among them, TLR7 recognises several single-stranded RNA viruses including SARS-CoV-2 6 . We previously showed that another RNA virus, hepatitis C virus (HCV), is able to inhibit CD4 T cell function via Toll-like receptor 7 (TLR7) 7 Here, we performed a nested case-control study (NCC) within our prospectively recruited GEN-COVID cohort with the aim to determine whether the 2 families described by van der Made et al. represent an ultra-rare situation or the tip of the iceberg of a larger subset of young male patients. We applied LASSO logistic regression analysis, after correcting for Principal Components, to a synthetic boolean representation of the entire set of genes of the X chromosome on the extreme phenotypic ends of the young male subset of the Italian GEN-COVID cohort (https://sites.google.com/dbm.unisi.it/gen-covid) 9 . Cases were selected according to the following inclusion criteria: i. male gender; ii. young age (<60 years); iii endotracheal intubation or CPAP/biPAP ventilation (79 subjects). As controls, 77 subjects were selected using the sole criterion of being oligo-asymptomatic not requiring hospitalization. Cases and controls represented the extreme phenotypic presentations of the GEN-COVID cohort. Exclusion criteria for both cases and controls were: i. SARS-CoV-2 infection not confirmed by PCR; ii. noncaucasian ethnicity. The materials and methods details are listed in the Online Repository section. The study (GEN-COVID) was consistent with Institutional guidelines and approved by the University Hospital (Azienda Ospedaliero-Universitaria Senese) Ethical Review Board, Siena, Italy (Prot n. 16929, dated March 16, 2020). Only rare variants (≤1% in European Non-Finnish All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint population) were considered in the boolean representation: the gene was set to 1 if it included at least a missense, splicing, or loss of function rare variant, and 0 otherwise. Fisher Exact test was then used for the specific data validation. Toll-like receptor 7 (TLR7) was picked up as one of the most important susceptibility genes by LASSO Logistic Regression analysis (Figure 1) . We then queried the COVID-19 section of the Network of Italian Genome NIG database (http://www.nig.cineca.it/, specifically, http://nigdb.cineca.it) that houses the entire GEN-COVID cohort represented by more than 1000 WES data of COVID-19 patients and SARS-CoV-2 infected asymptomatic subjects 7 . By selecting for young (<60 year-old) males, we obtained rare (MAF≤1%) TLR7 missense variants predicted to impact on protein function (CADD>12.28) in 5 out of 79 male patients (6,32%) with lifethreatening COVID-19 (hospitalized intubated and hospitalized CPAP/BiPAP) and in none of the 77 SARS-CoV2 infected oligo-asymptomatic male subjects. A similar Spanish cohort, composed of male patients under 60 years of age without comorbidities (77 cases and 45 controls) was used to expand the cohort to another representative European population highly impacted by COVID-19. All subjects were white European. The Spanish Covid HGE cohort is under IRB approval PR127/20 from Bellvitge University Hospital, Barcelona, Spain. We found a TLR7 variant in one of 77 cases (1,29%) and in none of 45 controls. Overall, the association between the presence of TLR7 rare mutations and severe COVID-19 was significant (p= 0.04 by Fisher Exact test, Table 1 ). We then investigated the presence of TLR7 mutations in the entire male cohort of COVID-19 (cases and controls) regardless of age. We found TLR7 rare missense variants in 3 additional patients over 60 years of age, including 2 among cases and 1 among controls, the last bearing the mutation p.Val222Asp predicted to have a low impact on protein function (CADD of 5.36) ( Table 2 ). In order to functionally link the presence of the identified TLR7 missense mutations and the effect on the downstream type I IFN-signaling, we performed a gene expression profile analysis in peripheral blood mononuclear cells (PBMCs) isolated from patients after stimulation All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint with the TLR7 agonist imiquimod (as reported by van der Made et al. 8 ). PBMCs from 5 out of 8 cases and from the control were available. All TLR7 variants were tested except one (Ala288Val) as some different patients share the same. This analysis showed a statistically significant decrease of IRF7 (member of the interferon regulatory transcription factor) and IFN-γ mRNA levels in all tested mutations (Val219Ile, Ser301Pro, Ala1032Thr, His630Tyr) identified in cases (P1, P3, P7, P8 and P6) compared with healthy (Ctl) demonstrating a complete impairment in IFN-and IFNγ production in response to TLR7 stimulation in all patients (Figure 2) . A similarly significant reduction was shown for ISG15 (Interferon-stimulated gene 15) and IFN-mRNA level for 4 out of 5 patients (P3, P8, P6, P7 ). An analogous trend was observed for TLR7 in P8 and P6 cases. A significant reduction was also shown for all TLR7-related mRNA transcripts when cases were compared with the asymptomatic controls (C1) (Supplementary Figure 1) . Interestingly, the p.Val222Asp variant proved to be functionally neutral in keeping with its discovery in control and not in cases (Figure 2) Segregation analysis was available for two of 8 cases, P3 and P6 (Figure 3) . In both pedigree, the disease nicely segregates as an X-linked disorder conditioned by environmental factors, i.e. SARS-Cov-2 (Figure 3, panel B) . This was also supported by functional analysis on all TLR7-related genes (Supplementary Figure 4) . As an example, we showed gene expression profile analysis for IRF7 gene: in male patients IRF7 mRNA levels are statistically significantly reduced compared to heterozygous females (Figure 3, panel A) . Of note, only the infected mutated male subject had severe COVID-19, whereas the infected not mutated female (sister) was oligosymptomatic with symptoms lasting 7-10 days; the infected mutated female (one of the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint daughters) was oligosymptomatic with symptoms lasting one month (Figure 3, panel C) . Both females did not require any hospital treatment. Our results showed that the two families with loss of function mutations reported by van der Made et al. 8 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint after stimulation with a TLR7 agonist for 4 hours. 5×10 5 PBMCs from COVID-19 patients and four unaffected male and female controls were stimulated for 4 hours with the TLR7 agonist imiquimod at 5 μ g/mL or cell culture medium. Quantitative PCR assay was performed and the 2 -IFN-α TLR7 Ctl C 1 P 1 P 3 P 8 P 6 P 7 mRNA fold change IRF7 Ctl C 1 P 1 P 3 P 8 P 6 P 7 ISG15 Ctl C 1 P 1 P 3 P 8 P 6 P 7 Ctl C 1 P 1 P 3 P 8 P 6 P 7 IFN-γ * * *** ** *** **** *** * * * * * * * * * * * * * * * Ctl C 1 P 1 P 3 P 8 P 6 P 7 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care Case Surveillance -United States Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy. Front Immunol Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7 ADDITIONAL INFORMATION Agostino Ognibene 29 , Antonella D'Arminio Monforte 30 , Esther Merlini 30 , Federica Gaia Miraglia 30 Infectious Diseases Unit, Misericordia Hospital 28) Territorial Scientific Technician Department Clinic of Infectious Diseases Italy 32) Department of Medical and Surgical Sciences for Children and Adults Infectious Diseases Clinic, Department of Medicine 2, Azienda Ospedaliera di Perugia and University of Perugia Italy 36) Department of Infectious Diseases, Treviso Hospital, Local Health Unit 2 Marca Trevigiana 39) Department of Molecular Medicine 45) Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital Clinical Trial Office, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital Infectious Diseases Clinic, Policlinico San Martino Hospital Study Coordinator Oncologia Medica e Ufficio Flussi 60) Department of Respiratory Diseases Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Carrer Baldiri i Reixac 4, 08028 *** ** ** All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this this version posted November 27, 2020. ; https://doi.org/10.1101/2020.11.19.20234237 doi: medRxiv preprint